Barbara de Graaff

Barbara de Graaff

Auto-generated profile, based on publicly available information

Barbara de Graaff

Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2014 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
LSL. Si
L. Si
TWT. M. Winzenberg
T. M. Winzenberg
BGB. de Graaff
B. de Graaff
APA. J. Palmer
A. J. Palmer

8 April 2019 in Australian and New Zealand Journal of Public Health
Verified
Journal Article
Open access
PDF file
FCFiona Cocker
Fiona Cocker
KYKwang Chien Yee
Kwang Chien Yee
APAndrew J. Palmer
Andrew J. Palmer
BGBarbara de Graaff
Barbara de Graaff
Objective: Assess national and jurisdictional incidence and mortality trends for primary liver cancer in Australia. Methods: Analysis of Australian Cancer Incidence and Mortality data published in 2017 by the AIHW. Age‐standardised rates (ASR) for 1982 to 2014/2015. Piecewise linear regression was used to assess temporal trends. For the purposes of comparison, data were also extracted for all cancers with greater burdens of disease (lung, colorectal, breast, prostate, pancreatic, and brain cancers and melanoma of the skin). Results: Since 1982, the average annual percentage change (AAPC) for ASR incidence of liver cancer was 4.858% (95%CI 4.558–5.563). This marked a 306% increase from 1.822/100,000 persons (95%CI 1.586–2.058) in 1982 to 7.396/100,000 persons (95%CI 7.069–7.723) in 2014. AAPC for ASR mortality was 3.013% (95%CI 2.448–3.521): an increase of 184% from 2.323/100,000 persons (95%CI 2.052–2.594) in 1982 to 6.593/100,000 (95%CI 6.290–6.896) in 2015. ASR incidence and mortality were highest in the NT (12.607/100,000 persons), VIC (8.229/100,000) and NSW (7.798/100,000). In comparison to the other selected cancers, higher AAPC for both incidence and mortality of liver cancer were observed. Conclusion: Incidence and mortality associated with liver cancer have increased substantially in the past three decades, in contrast to the improved outcomes observed for many other cancers. Jurisdictional incidence rates reflect higher prevalence of hepatitis B and C. Implications for public health: In the context of Australian cancer prevention and care programs, liver cancer is an outlier. Strategies to mitigate risk factors and improve surveillance of liver health for at‐risk groups are urgently required.

9 August 2022 in BMC Public Health
Verified
Journal Article
Open access
PDF file
NONneka Orji
Nneka Orji
JCJulie A. Campbell
Julie A. Campbell
KWKaren Wills
Karen Wills
MHMartin Hensher
Martin Hensher
APAndrew J. Palmer
Andrew J. Palmer
BGBarbara de Graaff
Barbara de Graaff
Background: ME/CFS is a disorder characterized by recurrent fatigue and intolerance to exertion which manifests as profound post-exertional malaise. Prevalence studies internationally have reported highly variable results due to the 20 + diagnostic criteria. For Australia, the prevalence of ME/CFS based on current case definitions is unknown. Objectives: To report prevalence of ME/CFS in patients aged ≥ 13 years attending Australian primary care settings for years 2015–2019, and provide context for patterns of primary care attendance by people living with ME/CFS. Methodology: Conducted in partnership with the Patient Advisory Group, this study adopted a mixed methods approach. De-identified primary care data from the national MedicineInsight program were analyzed. The cohort were regularly attending patients, i.e. 3 visits in the preceding 2 years. Crude prevalence rates were calculated for years 2015–2019, by sex, 10-year age groups, remoteness and socioeconomic status. Rates are presented per 100,000population (95% confidence intervals (CI)). Qualitative data was collected through focus groups and in-depth 1:1 interview. Results: Qualitative evidence identified barriers to reaching diagnosis, and limited interactions with primary care due to a lack of available treatments/interventions, stigma and disbelief in ME/CFS as a condition. In each year of interest, crude prevalence in the primary care setting ranged between 94.9/100,000 (95% CI: 91.5–98.5) and 103.9/100,000 population (95%CI: 100.3–107.7), equating to between 20,140 and 22,050 people living with ME/CFS in Australia in 2020. Higher rates were observed for age groups 50-59 years and 40-49 years. Rates were substantially higher in females (130.0–141.4/100,000) compared to males (50.9–57.5/100,000). In the context of the qualitative evidence, our prevalence rates likely represent an underestimate of the true prevalence of ME/CFS in the Australian primary care setting. Conclusion: ME/CFS affects a substantial number of Australians. Whilst this study provides prevalence estimates for the Australian primary care setting, the qualitative evidence highlights the limitations of these. Future research should focus on using robust case ascertainment criteria in a community setting. Quantification of the burden of disease can be used to inform health policy and planning, for this understudied condition.

23 February 2020 in Emergency Medicine Australasia
Verified
Journal Article
Closed access
PDF file
QTQuang Nhat Tran
Quang Nhat Tran
LLLeonard G Lambeth
Leonard G Lambeth
KSKristy Sanderson
Kristy Sanderson
BGBarbara de Graaff
Barbara de Graaff
MBMonique Breslin
Monique Breslin
ANAmanda L Neil
Amanda L Neil

12 June 2019 in Emergency Medicine Australasia
Verified
Journal Article
Closed access
PDF file
QTQuang Nhat Tran
Quang Nhat Tran
LLLeonard G Lambeth
Leonard G Lambeth
KSKristy Sanderson
Kristy Sanderson
BGBarbara de Graaff
Barbara de Graaff
MBMonique Breslin
Monique Breslin
ANAmanda L Neil
Amanda L Neil

22 December 2009 in Harm Reduction Journal
Verified
Journal Article
Open access
PDF file
SMStuart McLean
Stuart McLean
RBRaimondo Bruno
Raimondo Bruno
SBSusan Brandon
Susan Brandon
BGBarbara de Graaff
Barbara de Graaff
Background: Injections of mixtures prepared from crushed tablets contain insoluble particles which can cause embolisms and other complications. Although many particles can be removed by filtration, many injecting drug users do not filter due to availability, cost or performance of filters, and also due to concerns that some of the dose will be lost. Methods: Injection solutions were prepared from slow-release morphine tablets (MS Contin®) replicating methods used by injecting drug users. Contaminating particles were counted by microscopy and morphine content analysed by liquid chromatography before and after filtration. Results: Unfiltered tablet extracts contained tens of millions of particles with a range in sizes from < 5 μm to > 400 μm. Cigarette filters removed most of the larger particles (> 50 μm) but the smaller particles remained. Commercial syringe filters (0.45 and 0.22 μm) produced a dramatic reduction in particles but tended to block unless used after a cigarette filter. Morphine was retained by all filters but could be recovered by following the filtration with one or two 1 ml washes. The combined use of a cigarette filter then 0.22 μm filter, with rinses, enabled recovery of 90% of the extracted morphine in a solution which was essentially free of tablet-derived particles. Conclusions: Apart from overdose and addiction itself, the harmful consequences of injecting morphine tablets come from the insoluble particles from the tablets and microbial contamination. These harmful components can be substantially reduced by passing the injection through a sterilizing (0.22 μm) filter. To prevent the filter from blocking, a preliminary coarse filter (such as a cigarette filter) should be used first. The filters retain some of the dose, but this can be recovered by following filtration with one or two rinses with 1 ml water. Although filtration can reduce the non-pharmacological harmful consequences of injecting tablets, this remains an unsafe practice due to skin and environmental contamination by particles and microorganisms, and the risks of blood-borne infections from sharing injecting equipment.